Q&A: John Ioannidis Talks Transparency in Biomedical Literature

The Stanford University researcher discusses a new study on measures such as data sharing and funding disclosures.

Written byShawna Williams
| 3 min read
an abstract image suggesting blocks of data

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

ABOVE: © ISTOCK.COM, BLACKJACK3D

John Ioannidis is a Stanford University epidemiologist known for his blunt critiques of the scientific enterprise, such as the 2005 paper “Why Most Published Research Findings are False.” In a new report out today (November 20) in PLOS Biology, he and colleagues follow up on an earlier study in which they found authors weren’t so good on measures of transparency and reproducibility, such as sharing their data and protocols and disclosing funders.

The new analysis, which scrutinizes 149 randomly selected biomedical research papers published between 2015 and 2017, finds some improvements. We spoke with Ioannidis to get his take on the results.

The Scientist: What did you set out to do in this latest study, and what, to you, are its main takeaways?

John Ioannidis: We had previously assessed the same indicators in papers published in the biomedical literature from 2000 to 2014. We wanted to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Shawna was an editor at The Scientist from 2017 through 2022. She holds a bachelor’s degree in biochemistry from Colorado College and a graduate certificate in science communication from the University of California, Santa Cruz. Previously, she worked as a freelance editor and writer, and in the communications offices of several academic research institutions. As news director, Shawna assigned and edited news, opinion, and in-depth feature articles for the website on all aspects of the life sciences. She is based in central Washington State, and is a member of the Northwest Science Writers Association and the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies